Twist Bioscience (TWST)

Executive Summary

Twist Bioscience is a publicly traded synthetic biology company that leverages a proprietary silicon-based DNA synthesis platform to manufacture high-quality synthetic DNA products, including gene synthesis, oligo pools, exome capture, NGS target enrichment, and variant libraries. Founded in 2013 and headquartered in South San Francisco, the company serves a diverse customer base across research, biopharma, and diagnostics. Its core technology enables high throughput, accuracy, and scalability, positioning it as a key enabler in the genomics and synthetic biology markets. Despite a competitive landscape, Twist's platform advantages and expanding commercial product portfolio (7 commercial products) support its growth trajectory. The company has a market valuation of ~$3.6B with a strong cash position to fund R&D and commercialization. Recent focus includes partnerships with biopharma for antibody discovery, CRISPR-based gene editing tools, and long-read sequencing applications. The terminated Phase 1 trial (Human mAb 216 + Vincristine) is not central to its current strategy, as Twist primarily operates as a platform technology provider.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Express Genes or Long-Read Sequencing Kits75% success
• TBDMajor Biopharma Partnership for Antibody Discovery or CRISPR Libraries60% success
• Q3 2026Q3 FY2026 Earnings Beat with Raised Guidance65% success